The final results of a trial of Paxlovid conducted by Pfizer shows 89% cut of risk of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.
A final results of trial of Paxlovid conducted by Pfizer shows 89% cut of risl of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.
A final results of trial of Paxlovid conducted by Pfizer shows 89% cut of risk of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.
The final results ofa trial of Paxlovid conducted by Pfizer shows 89% cut of risk of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.